In summary, our findings provided deep insights into the radioresistance of NEK2 in ESCC, elucidating the significant clinical implications of NEK2 knockdown as a promising therapeutic strategy for ESCC. Here, NEK2 is linked to esophageal squamous cell carcinoma.